Spots Global Cancer Trial Database for Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Official Title: Safety and Efficacy of Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy: a Single-arm, Phase 3 Study
Study ID: NCT02486354
Conditions
Interventions
Study Description
Brief Summary: This study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based chemotherapy regimen.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Bejing Cancer Hospital, Beijing, Beijing, China
307 Hospital of PLA, Beijing, Beijing, China
Beijing Chest Hospital, Beijing, Beijing, China
Third Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China
Sun yat-sen Univerisity Cancer Center, Guanzhou, Guangdong, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Yan Sun, MD
Affiliation: Cancer Hospital, Chinese Academy of Medical Science
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
